One clinical trial (NCT02923284) evaluated two biomarkers (urinary AQP1 and PLIN2) as a low-cost screening method to discriminate benign renal masses and patients with RCC from healthy controls [14]. Here, AQP1 is linked to renal cell carcinoma.